Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning new therapeutic breakthroughs in systemic diseases like lupus and polymyalgia rheumatica, a refinement of our approach to common conditions like osteoarthritis, and a look at the future of rheumatology through the lenses of precision medicine and health equity. Let's dive in.

This week's papers:

1. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. — JAMA 2026
2. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. — The New England journal of medicine 2026
3. Obexelimab for the Treatment of IgG4-Related Disease. — The New England journal of medicine 2026
4. Invisible pain, visible impact: the urgent need to prioritise women's health in rheumatic and musculoskeletal diseases. — Annals of the rheumatic diseases 2026
5. Evaluating machine learning tools to assist title and abstract screening in systematic literature reviews: a report based on the EULAR RA Management Recommendations Task Force. — Annals of the rheumatic diseases 2026
6. OA Fundamentals Series: DIAGNOSIS AND CLINICAL ASSESSMENT OF OSTEOARTHRITIS. — Osteoarthritis and cartilage 2026
7. Integrated Clinical and Proteomic Profiling of CD19 CAR-T Cell Therapy in Progressive Systemic Sclerosis. — Arthritis & rheumatology (Hoboken, N.J.) 2026
8. Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseases. — Annals of the rheumatic diseases 2026
9. Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. — Lancet (London, England) 2026
10. Towards global clinical practice guidelines for the management of non-specific low back pain in primary care: a review of current guideline recommendations and how they have changed over the last 30 years. — The Lancet. Rheumatology 2026

Listen at AudioScholar